Having just won an FDA nod for its GLP-1 diabetes contender Adlyxin, Sanofi will be going up against some entrenched rivals in its fight for market share. But new data from healthcare informatics firm ...

No increase in serious hypoglycemia, hyperglycemia after switch from analogue to human insulin. A recent posting on the FDA's Drug Shortages tracker indicates that the product has been discontinued.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has approved the once-daily glucagon-like ...

Sanofi announced that the Food and Drug Administration (FDA) has approve Adlyxin (lixisenatide) injection as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. Sanofi ...

HealthDay News — Adlyxin (lixisenatide), a glucagon-like peptide-1 receptor agonist, has been approved by the US Food and Drug Administration to treat type 2 diabetes in adults, the agency said ...

Paris, France - July 28, 2016 - Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection ...

Lixisenatide is a Zealand-invented once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. Zealand licensed the global development and commercialization rights to lixisenatide ...

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 ...

THURSDAY, July 28, 2016 -- Adlyxin (lixisenatide) has been approved by the U.S. Food and Drug Administration to treat type 2 diabetes in adults, the agency said Thursday in a news release. As the FDA ...

Paris, France - July 28, 2016 - Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection ...